AbbVie's Botox patent lawsuit is 'very unlikely to derail' Revance's rival launch: analysts

For a small company seeking to market a rival to a dominant brand, a patent lawsuit from a global pharma giant would seem to be a cause for concern. But Revance has a good chance of beating back AbbVie's recent patent case, one team of analysts figures.